Oncology Archives - Page 18 of 23

Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and Switzerland

Authors: D Deeren, S Balabanov, K Nickel, C Giannopoulou, S Gonzalez-McQuire, L Kutikova, W Bouwmeester, A Spyridonidis Published: Leukemia Research, 2020 View publication Objectives To describe real-world management and clinical and economic...

Costs and cost drivers associated with non-small-cell lung cancer patients who received two or more lines of therapy in Europe

Authors: K Verleger, J R Penrod, M M Daumont, C Solem, L Luo, C Macahilig, N Hertel Published: ClinicoEcnommics and Outcomes Research, 2020 View publication Purpose Advanced non-small-cell lung cancer (aNSCLC; stage...

Development of an initial conceptual model of multiple myeloma to support clinical and health economics decision making

Authors: S Gonzalez-McQuire, M A Dimopoulos, K Weisel, W Bouwmeester, R Hajek, M Campioni, C Bennison, W Xu, K Pantiri, M Hensen, E Terpos, S Knop Published: MDM Policy & Practice, 2019...

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis

Authors: D F McDermott, R Shah, K Gupte-Singh, J Sabater, L Luo, M Botteman, S Rao, M M Regan, M Atkins Published: Quality of life research, 2019 View publication Purpose To compare...

Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy

Authors: A Shah, R Shah, N Kebede, A Mohamed, M Botteman, R Waldeck, A Hussain Published: Journal of Medical Economics, 2019 View publication Aims To describe the incidence and identify prognostic factors...

Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials – Part 2: Clinical Benefit and Patient Preference”, has sparked our interest. This blog...

Methodology of a novel risk stratification algorithm for patients with multiple myeloma in the relapsed setting

Authors: W Bouwmeester, A Briggs, B van Hout, R Hajek, S Gonzalez-McQuire, M Campioni, L DeCosta, L Brozova Published: Oncology and Therapy, 2019 View publication Introduction Risk stratification tools provide valuable information...

Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan

Authors: R Shah, M Botteman, R Waldeck Published: Future Oncology, 2019 View publication Aim We conducted this study to describe nonmetastatic castration-resistant prostate cancer (nmCRPC) patient characteristics and treatment patterns in the...

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma

Authors: R Hájek, M Delforge, M S Raab, P Schoen, L DeCosta, I Spicka, J Radocha, L Pour, S Gonzalez-McQuire, W Bouwmeester Published: British Journal of Heamatology, 2019 View publication Abstract Multiple...

News